格隆汇12月15日丨康辰药业(603590.SH)公布，公司自主研发的KC1036片（简称"KC1036"），顺利完 成"KC1036 联合 PD-1 抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌临床试验（KC1036-COM- 01）"首例受试者入组服药。 KC1036 是公司自主研发的化学药品 1 类创新药，公司拥有该产品的全球知识产权。KC1036 通过抑制 VEGFR2、AXL 等多靶点实现抗肿瘤活性。KC1036具有较强的 VEGFR 血管靶向，抑制肿瘤细胞生 长；通过抑制AXL，可以改善宿主的抗肿瘤免疫应答，从而避免肿瘤的免疫逃逸。 目前 KC1036 针对消化系统肿瘤、胸腺肿瘤、儿童尤文肉瘤等多个适应症正在开展临床研究，截至目 前，已有超 300 例受试者入组 KC1036 临床研究，现有临床研究结果显示了突出的抗肿瘤活性、以及良 好的安全性和耐受性。 ...

南财智讯12月15日电，康辰药业公告，公司于2025年12月15日召开第四届董事会第二十二次会议及第四 届监事会第十八次会议，审议通过《关于部分募投项目结项并将剩余募集资金永久补充流动资金的议 案》。本次拟结项的募投项目为"创新药研发及靶向抗肿瘤药物创新平台建设项目"，包含四个子项目， 其中"靶向抗肿瘤药物创新平台建设项目"和"创新药药物发现项目"已完成，已达到预定可使用状 态；"CX1026项目"和"CX1003项目"拟不再继续投入。截至2025年11月30日，该项目募集资金专用账户 余额为4298.21万元，全部为资金利息或理财收益，具体金额以资金转出当日账户余额为准，拟全部用 于永久性补充流动资金。公司将在股东大会审议通过后办理资金划转，并在募集资金全部转出后注销相 应募集资金专户。该事项尚需提交公司股东大会审议。 ...

Market Overview - The Shanghai Composite Index closed at 3900.50 points, with a decline of 0.23% [1] - The total trading volume of A-shares reached 1,791.634 billion yuan [1] Moving Average Crossovers - A total of 92 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Delisted Suwu: -6.71% - Dayou Energy: -2.31% - Pulian Software: -2.08% [1] Individual Stock Performance - Delisted Suwu (600200) saw a price drop of 10.00% with a trading turnover rate of 8.15% [1] - Dayou Energy (600403) increased by 0.52% with a turnover rate of 1.72% [1] - Pulian Software (300996) decreased by 1.63% with a turnover rate of 3.97% [1] - Other notable stocks include: - Kangchen Pharmaceutical (603590): +0.45%, turnover rate 1.80% - Zhengzhou Coal (600121): unchanged, turnover rate 2.38% [1] Additional Stock Insights - Stocks with minor declines include: - Jierong Technology (002855): -6.14%, turnover rate 4.60% - United (003042): -3.64%, turnover rate 4.78% [1] - Stocks with slight increases include: - Haohua Energy (601101): +1.25%, turnover rate 0.68% - China Petroleum (601857): -1.23%, turnover rate 0.06% [1]

Core Viewpoint - The A-share market is experiencing a slight decline, with the Shanghai Composite Index down by 0.32% and a total trading volume of 1.456 trillion yuan, indicating a cautious market sentiment [1]. Group 1: Market Performance - As of 14:05, the Shanghai Composite Index stands at 3896.93 points, reflecting a decrease of 0.32% [1]. - The total trading volume in the A-share market is reported at 1.456 trillion yuan [1]. Group 2: Moving Averages Analysis - A total of 93 A-shares have seen their 5-day moving averages cross below their 10-day moving averages, indicating potential bearish trends [1]. - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - **退市苏吴**: 5-day MA is 0.88 yuan, 10-day MA is 0.94 yuan, with a difference of -6.71% [1]. - **大有能源**: 5-day MA is 7.97 yuan, 10-day MA is 8.16 yuan, with a difference of -2.36% [1]. - **普联软件**: 5-day MA is 17.69 yuan, 10-day MA is 18.06 yuan, with a difference of -2.04% [1]. Group 3: Individual Stock Movements - **康辰药业**: Today's change is +0.52%, with a 5-day MA of 43.15 yuan and a 10-day MA of 43.81 yuan, showing a difference of -1.52% [1]. - **郑州煤电**: Today's change is -0.23%, with a 5-day MA of 4.43 yuan and a 10-day MA of 4.50 yuan, showing a difference of -1.47% [1]. - **捷荣技术**: Today's change is -5.65%, with a 5-day MA of 18.79 yuan and a 10-day MA of 18.99 yuan, showing a difference of -1.07% [1].

Core Points - The company has decided to repurchase and cancel a total of 346,000 restricted stocks due to four incentive recipients no longer qualifying for the incentive program after leaving the company [2][4][5] Group 1: Repurchase and Cancellation Details - The repurchase and cancellation of restricted stocks were approved during multiple board meetings held on April 25, June 23, and August 27, 2025 [3][4] - The repurchase involves 140,000 shares from one recipient and 206,000 shares from three other recipients [2][3] - The company has opened a dedicated securities account for the repurchase process and expects the cancellation to be completed by December 8, 2025 [5][6] Group 2: Legal and Compliance Aspects - The company has confirmed that the decision-making process and information disclosure comply with relevant laws and regulations, including the "Management Measures for Equity Incentives of Listed Companies" [7][8] - A legal opinion from Beijing Guofeng Law Firm states that the procedures followed for the repurchase and cancellation are in accordance with applicable regulations [8]

证券代码：603590 证券简称：康辰药业 公告编号：临2025-076 北京康辰药业股份有限公司关于2023年限制性股票激励计划回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 重要内容提示： ● 回购注销原因：根据公司《2023年限制性股票激励计划》的有关规定，鉴于4名激励对象，因离职不 再具备激励对象资格，其已获授但尚未解除限售的限制性股票由公司进行回购注销，经公司董事会、股 东大会审议同意公司回购注销4名激励对象已获授但尚未解除限售的限制性股票共计346,000股。 ● 本次注销股份的有关情况 ■ 一、本次限制性股票回购注销的决策与信息披露 北京康辰药业股份有限公司（简称"公司"）于2025年4月25日召开了第四届董事会第十六次会议和第四 届监事会第十三次会议，审议通过了《关于回购注销部分激励对象已获授但尚未解除限售的限制性股票 及调整回购价格的议案》，同意公司回购注销1名激励对象已获授但尚未解除限售的140,000股限制性股 票。 公司于2025年6月 ...

（文章来源：证券日报） 证券日报网讯 12月3日晚间，康辰药业发布公告称，鉴于4名激励对象因离职不再具备激励对象资格， 其已获授但尚未解除限售的限制性股票由公司进行回购注销，经公司董事会、股东大会审议同意公司回 购注销4名激励对象已获授但尚未解除限售的限制性股票共计346，000股。 ...

北京康辰药业股份有限公司 关于 2023 年限制性股票激励计划回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：根据公司《2023 年限制性股票激励计划》的有关规定， 鉴于 4 名激励对象，因离职不再具备激励对象资格，其已获授但尚未解除限售的 限制性股票由公司进行回购注销，经公司董事会、股东大会审议同意公司回购注 销 4 名激励对象已获授但尚未解除限售的限制性股票共计 346,000 股。 | | | | 回购股份数量（股） | 注销股份数量（股） | 注销日期 | | | | --- | --- | --- | --- | --- | | 346,000 | 346,000 | 年 月 2025 | 12 | 日 8 | 证券代码：603590 证券简称：康辰药业 公告编号：临 2025-076 根据《上市公司股权激励管理办法》、公司《2023 年限制性股票激励计划》 的有关规定，鉴于 4 名激励对象，因离职不再具备激励对象资格，其已获授但尚 未解除限售的限制性股票共计 346, ...

北京国枫律师事务所 关于北京康辰药业股份有限公司 2023 年限制性股票激励计划 回购注销部分限制性股票实施情况的 法律意见书 国枫律证字[2023]AN138-8 号 GRANDWAY 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编: 100005 电话（Tel） 010-88004488/66090088 传真（Fax): 010-66090016 北京国枫律师事务所 关于北京康辰药业股份有限公司 2023 年限制性股票激励计划 回购注销部分限制性股票实施情况的 法律意见书 国枫律证字[2023]AN138-8号 致:北京康辰药业股份有限公司 一、本激励计划回购注销事项履行的程序 经查验康辰药业相关董事会、监事会、股东大会的会议文件及公告,康辰药业 本次回购注销事项已履行的批准和授权及信息披露如下: 1. 2023年8月16日,公司召开 2023年第三次临时股东大会,会议审议通过了 《关于<公司 2023 年限制性股票激励计划(草案)>及其摘要的议案》《关于<公司 2023 年限制性股票激励计划实施考核管理办法>的议案》《关于 ...

Core Viewpoint - The A-share market showed a decline with the Shanghai Composite Index closing at 3878.00 points, down 0.51% and below the five-day moving average, with a total trading volume of 168.36 billion yuan [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3878.00 points, reflecting a decrease of 0.51% [1]. - The total trading volume in the A-share market reached 168.36 billion yuan [1]. Group 2: Stocks Breaking the Five-Day Moving Average - A total of 233 A-shares broke above the five-day moving average today [1]. - Notable stocks with significant deviation rates include: - Sifangda (300179) with a deviation rate of 12.01% and a daily increase of 15.37% [1]. - *ST Changyao (300391) with a deviation rate of 11.26% and a daily increase of 20.09% [1]. - Jindike (688670) with a deviation rate of 8.49% and a daily increase of 15.93% [1]. Group 3: Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that just crossed the five-day moving average include: - Jiuli Special Materials (300996) with a deviation rate of 8.38% and a daily increase of 11.38% [1]. - Zhongheng Design (603017) with a deviation rate of 8.14% and a daily increase of 9.98% [1]. - Shuangqiang Technology (001211) with a deviation rate of 7.13% and a daily increase of 9.99% [1].